Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib? – PubMed
The phase 3 PROfound trial led to the recent approval of the PARP inhibitor olaparib for men with metastatic castration-resistant prostate cancer and mutations in homologous recombination repair genes. We raise methodological concerns about the trial, including: a suboptimal control arm, problematic …